We are advancing a clinical stage pipeline of novel product candidates in two key areas of energy metabolism: cardiovascular disease and inborn errors of metabolism.

Our lead program, ninerafaxstat, is currently in Phase 2 clinical development for conditions of oxygen deprivation in the heart. The initial indications we are targeting with ninerafaxstat are non-obstructive hypertrophic cardiomyopathy, heart failure and stable angina. Our additional product candidate, IMB-203 is designed to address the energy deficiency in patients with rare genetic mutations in mitochondrial metabolism, including those with propionic acidemia and other inborn errors of metabolism.


For the Treatment of Cardiovascular Diseases

Read more


For the Treatment of Inborn Errors of Metabolism

Read more